缬沙坦治疗轻、中度原发性高血压的临床研究──附117例报告  

Clinical study on treating mild to moderate essential hypertension with valsartan

作　　者：曾群英[1] 麦炜颐[1] 何清[1] 陈国伟[1] 高修仁[1] 

机构地区：[1]中山医科大学附属第一医院心内科,510080

出　　处：《新医学》2000年第12期716-718,共3页Journal of New Medicine

摘　　要：目的：评价缬沙坦治疗轻、中度原发性高血压的临床疗效及安全性。方法：缬沙坦组（５９例，８０ ｍｇ／ｄ至１６０ ｍｇ／ｄ）和氯沙坦组（对照组，５８例，５０ ｍｇ／ｄ至１００ ｍｇ／ｄ）均连续服药半年。结果：两组总有效率、降压幅度、收缩压和舒张压的各／峰比值分别为７５％和 ７４％、 ３．５ ｋＰａｔ２．０ ｋＰａ和 ３．４ ｋＰａ／２．１ｋＰａ、０．８２和０．８１、０．７８和０．７９，组间比较均无显著性差异（Ｐ＞０．０５）；两组治疗后血浆肾素活性、血管紧张素Ⅱ均升高（Ｐ＜０．０５～０．０１）；醛固酮、内皮素均降低（均为Ｐ＜０．０５），但组间比较无显著性差异（Ｐ＞０．０５）。血尿酸也明显下降（均为Ｐ＜０．０５），基础值越高，降幅越大，且氯沙坦组更显著（Ｐ＜０．０５）。随访半年，两组心、脑血管事件发生率相似（Ｐ＞０．０５），两组不良反应轻微。结论：缬沙坦的疗效与氯沙坦相近，值得临床推广应用。Objective: To evaluate the clinical effects and safety of treating mild and moderate essential hypertension with valsartan. Methods: One hundred and seventeen cases were assigned into two groups, one were treated with valsartan 80 mg^160 mg, another with losartan 50 mg^l00 mg once daily for half a year. Results: The total effective rate, amplitude of blood pressure reduced, T/P ratio of systolic and diastolic blood pressure in valsartan and losartan group were 75% and 74%, 3.5 kPa/2.0 kpa and 3.4 kPa/2.1 kPa, 0.82 and 0.81, 0.78 and 0.79 respectively. No significant differences existed between two groups (P>0.05). Plasma renin activity (PRA) and angiotensin Ⅱ elevated after the therapy (P <0.05~0.01), while aldosterone and endothelin (ET) decreased (P<0.05) in both groups, there were no significant differences between two groups (P >0.05). Uric acid level of blood also reduced after the treatment, and the higher the level before the therapy, the larger the amplitude reduced. The amplitude reduced was larger in losartan group (P<0.05). The cardiocerebral events of two groups were similar during therapy. Adverse reactions in valsartan group were mild. Conclusion: Valsartan is a new angiotensin Ⅱ type 1 receptor (AT1) antagonist with similar effect of losartan and worths recommending in clinical practice..

关 键 词：缬沙坦 氯沙坦 原发性高血压 血管紧张素Ⅱ1型受体拮抗药 治疗结果 

分 类 号：R544.1[医药卫生—心血管疾病]